United-Imaging-Logo

Nuclear Medicine

BIR publishes updated IR(ME)R clinical practice guidance
By AuntMinnieEurope.com staff writers
The updated guidance covers responsibilities and includes practical scenarios to support local interpretation and implementation.
September 8, 2026
Irmer Guidance Front Cover
Q&A with Ken Herrmann: Theranostics must move earlier and beyond established targets
By Claudia Tschabuschnig
Prof. Ken Herrmann discusses the expansion of radioligand therapy into earlier treatment lines, the need for new cancer targets, long-term safety, and the challenge of translating innovation into robust clinical evidence.
September 1, 2026
Prof. Ken Herrmann, director of the Department of Nuclear Medicine at University Hospital Essen, pictured fourth from the left, at the opening opening of a new nuclear medicine center in Essen, Germany, focused on theranostics and personalized cancer care.
Video: Ken Herrmann maps nuclear medicine’s next frontiers
By Claudia Tschabuschnig
From earlier PSMA-targeted therapy and new cancer targets to total-body PET and low-dose screening, Prof. Ken Herrmann outlines where nuclear medicine could go next.
August 31, 2026
Ken Herrman1
SPECT, PET refine contemporary cardiac amyloidosis assessment
By Claudia Tschabuschnig
Experts highlighted SPECT/SPECT-CT as central to reliable cardiac amyloidosis imaging, while emerging PET tracers may improve early detection, disease characterization, and follow-up.
August 24, 2026
Shutterstock 2437656775
Swiss nuclear medicine seeks rules fit for radiopharmaceutical innovation
By Claudia Tschabuschnig
Funding, advanced technology, and the country’s small scale help make Switzerland an innovative environment for nuclear medicine.
August 27, 2026
Antoine Leimgruber
Leimgruber: Nuclear medicine needs regulation fit for innovation
By Claudia Tschabuschnig
In a video interview, Dr. Antoine Leimgruber, director ofdevelopment for nuclear medicine at Swiss Medical Network in Genolier, Switzerland, explores what is already changing in nuclear medicine and what continues to hold the specialty back.
August 26, 2026
Laim
ITM receives Complete Response Letter for ITM-11
By AuntMinnie.com staff writers
The FDA stated that it's unable to approve the NDA in its present form.
August 10, 2026
Nuclear Medicine
ITM launches new oncology therapeutics division
By AuntMinnie.com staff writers
Lumara Bio will focus resources toward commercial readiness for ITM's lead drug candidate, lutetium-177 (Lu-177) edotreotide (ITM-11).
July 27, 2026
Lumara
Actineer completes Ra-226 recycling process to support Ac-225 supply
By AuntMinnie.com staff writers
This process aims to improve Ac-225 supply predictability and cost stability, as well as reduce waste generation.
July 14, 2026
Nuclear Medicine Worker Sm
Ratio Therapeutics signs Ac-225 supply agreement with PanTera
By AuntMinnie.com staff writers
Deal will support Ratio's alpha therapy programs.
June 30, 2026
Business Deal Corporate 400
Novel SST2-PET tracer shows promise in patients with NETs
By Will Morton
With a half-life of 3.3 hours, cyclotron-produced Cu-61 NODAGA-LM3 could allow delayed imaging and centralized distribution.
June 25, 2026
Maximum intensity projections showing biodistribution of Cu-61 NODAGA-LM3 (146 MBq) in a patient with a metastatic non-functional NET of the pancreas G2 (Ki-67: 5%) with lymph node, hepatic, osseous, and peritoneal as well as ovarian metastases. PET performed a 1-hour, 3-hours, and 18-hours post-injection show high and prolonged tumor uptake and excellent image contrast, with low uptake in the liver, intestinal tract, and other non-target organs.
Curium to invest €32M in French radiopharmaceutical facility
By AuntMinnieEurope.com staff writers
The investment will go toward development of a new production line for lutetium-177 PSMA-I&T, a targeted radioligand therapy.
June 1, 2026
France Flag Button 400
Page 1 of 6
Next Page